Summary
Global Markets Direct’s, ‘Oropharyngeal Cancer - Pipeline Review, H1 2016’, provides an overview of the Oropharyngeal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer
- The report reviews pipeline therapeutics for Oropharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Oropharyngeal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Oropharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Oropharyngeal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Advaxis, Inc.
AstraZeneca Plc
Genticel S.A.
Kolltan Pharmaceuticals, Inc.
Merck & Co., Inc.
Novartis AG
PNP Therapeutics, Inc.
Synta Pharmaceuticals Corp.
VLPbio
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oropharyngeal Cancer Overview 8
Therapeutics Development 9
Pipeline Products for Oropharyngeal Cancer - Overview 9
Pipeline Products for Oropharyngeal Cancer - Comparative Analysis 10
Oropharyngeal Cancer - Therapeutics under Development by Companies 11
Oropharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 12
Oropharyngeal Cancer - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Oropharyngeal Cancer - Products under Development by Companies 16
Oropharyngeal Cancer - Products under Investigation by Universities/Institutes 17
Oropharyngeal Cancer - Companies Involved in Therapeutics Development 18
Advaxis, Inc. 18
AstraZeneca Plc 19
Genticel S.A. 20
Kolltan Pharmaceuticals, Inc. 21
Merck & Co., Inc. 22
Novartis AG 23
PNP Therapeutics, Inc. 24
Synta Pharmaceuticals Corp. 25
VLPbio 26
Oropharyngeal Cancer - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
alpelisib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
axalimogene filolisbac - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ganetespib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
gedeptin - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
GTL-001 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
HNVax - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
KTN-3379 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
LN-145 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
nimotuzumab - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
olaparib - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
pembrolizumab - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
PGV-001 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
TT-12 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Oropharyngeal Cancer - Recent Pipeline Updates 78
Oropharyngeal Cancer - Dormant Projects 131
Oropharyngeal Cancer - Product Development Milestones 132
Featured News & Press Releases 132
Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform 132
Sep 14, 2015: FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac in HPV-Associated Head and Neck Cancer 133
Appendix 135
Methodology 135
Coverage 135
Secondary Research 135
Primary Research 135
Expert Panel Validation 135
Contact Us 135
Disclaimer 136
List of Tables
Number of Products under Development for Oropharyngeal Cancer, H1 2016 9
Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Investigation by Universities/Institutes, H1 2016 17
Oropharyngeal Cancer - Pipeline by Advaxis, Inc., H1 2016 18
Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, H1 2016 19
Oropharyngeal Cancer - Pipeline by Genticel S.A., H1 2016 20
Oropharyngeal Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 21
Oropharyngeal Cancer - Pipeline by Merck & Co., Inc., H1 2016 22
Oropharyngeal Cancer - Pipeline by Novartis AG, H1 2016 23
Oropharyngeal Cancer - Pipeline by PNP Therapeutics, Inc., H1 2016 24
Oropharyngeal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 25
Oropharyngeal Cancer - Pipeline by VLPbio, H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Oropharyngeal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 78
Oropharyngeal Cancer - Dormant Projects, H1 2016 131
List of Figures
Number of Products under Development for Oropharyngeal Cancer, H1 2016 9
Number of Products under Development for Oropharyngeal Cancer - Comparative Analysis, H1 2016 10
Number of Products under Development by Companies, H1 2016 11
Number of Products under Investigation by Universities/Institutes, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 15
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Top 10 Targets, H1 2016 28
Number of Products by Stage and Top 10 Targets, H1 2016 28
Number of Products by Mechanism of Actions, H1 2016 30
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 30
Number of Products by Routes of Administration, H1 2016 32
Number of Products by Stage and Routes of Administration, H1 2016 32
Number of Products by Molecule Types, H1 2016 34
Number of Products by Stage and Molecule Types, H1 2016 34
